Today, we released our second quarter 2024 financial results. We are keenly focused on executing on the strategic plans we made during the first half of 2024, including our expansion into autoimmune diseases and continued advancement of our oncology pipeline, each facilitated by our recent oversubscribed financing. Learn more: https://bit.ly/46GQh8Y
Cullinan Therapeutics
Biotechnology Research
Cambridge, Massachusetts 6,910 followers
Modality-Agnostic Targeted Therapeutics
About us
Cullinan Therapeutics is dedicated to creating new standards of care for patients. We have strategically built a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Our portfolio encompasses a wide range of modalities, each with the potential to be best and/or first in class. Anchored in a deep understanding of oncology, immunology, and translational medicine, we create differentiated ideas, identify the most appropriate targets, and select the optimal modality to develop transformative therapeutics across a wide variety of cancer and autoimmune indications. Notice to Job Seekers: Job applicants should be aware of job recruitment, interview and offer scams being perpetrated through the use of the internet and social media platforms. To learn more, visit our Careers page or read Cullinan’s Employment Recruitment Scams Notice here: https://cullinantherapeutics.com/docs/employment-recruitment-scams-notice.pdf
- Website
-
http://www.cullinantherapeutics.com
External link for Cullinan Therapeutics
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Cambridge, Massachusetts
- Type
- Public Company
- Specialties
- Oncology and Auto-Immune Diseases
Locations
-
Primary
1 Main St
Cambridge, Massachusetts 02142, US
Employees at Cullinan Therapeutics
Updates
-
On Monday, August 5, Nadim Ahmed, President and CEO, and Jeff Jones, Chief Medical Officer, will participate in a fireside chat at the BTIG Virtual Biotechnology Conference.
-
This #WorldLungCancerDay, we recognize the bravery of those living with lung cancer and their loved ones. We are grateful we can work with incredible scientists and patients who participate in clinical trials to help collectively advance our understanding of disease and how new medicines work. We are committed to creating safer, more effective treatments to bring hope and new standards of care to those living with cancer. #WLCD24 Learn more about the diseases our programs support, including non-small cell lung cancer: https://lnkd.in/ewv-DPJw
-
In our recently published manuscript, we explore preclinical findings with CLN-617, our tumor-retained single-chain dual cytokine fusion protein, in syngeneic mouse tumor models. CLN-617 is comprised of IL-2, leukocyte-associated immunoglobulin-like receptor 2 (LAIR2), human serum albumin (HSA), and IL-12. Read the full research article “CLN-617 retains IL-2 and IL-12 in injected tumors to drive robust and systemic immune-mediated antitumor activity” in Cancer Immunology Research by American Association for Cancer Research.
-
Our team has a broad range of diverse skills, perspectives, and expertise, but there are two things we all have in common: We enjoy what we do, and we enjoy doing it together. Stephen Andre, our Chief Human Resources Officer, highlights our culture of collaboration and respect across the organization and the future of our team’s culture. https://bit.ly/3RrgfXr
-
We’re proud to share Patrick A. Baeuerle, PhD, our Co-Founder and Chief Scientific Advisor, was recognized again this year by Research.com’s 2024 Ranking of Best Scientists in the field of #Biology and #Biochemistry. With more than 30 years in the industry, Patrick has been published in hundreds of peer-reviewed scientific papers that have been cited more than 83,000 times. This impressive body of evidence underscores his commitment to transformative scientific progress. Learn more about Patrick’s accomplishments and contributions to the industry here: https://bit.ly/3zG6azL
Patrick A. Baeuerle Ranked Among 2024’s Best Scientists
research.com
-
In case you missed Sachs Associates’ Annual Oncology Innovation Forum, be sure to watch the full panel discussion, “New Endpoints for Early-Stage Oncology Companies” featuring Nadim Ahmed, President and CEO. #Sachs_OIF
We are delighted to share the New Endpoints for Early-Stage Oncology Companies Panel from the 10th Annual Oncology Innovation Forum. Chaired by: Jeff Bockman, EVP Expert Advisor, Oncology, Lumanity Head, Oncology Center of Excellence, Lumanity Panellists: Colette Lipp, Director, Global BD Oncology & Immuno-Oncology, Merck KGaA, Darmstadt, Germany Jim Barlow, President & CEO, ImmunoGenesis, Inc. Matthew Price, Co-Founder, EVP & Chief Operating Officer, Promontory Therapeutics Inc. Nadim Ahmed, President & CEO, Cullinan Therapeutics, Inc. Raven Lin, Co-Founder & CEO, Pilatus Biosciences SA View here: https://lnkd.in/d8q8SAcz #OncologyEndpoints #EarlyStageOncology #CancerResearch #BiotechInnovation #Pharma #SachsForum #ASCO2024
New Endpoints for Early-Stage Oncology Companies Panel @ Sachs_OIF
https://www.youtube.com/
-
This Pride Month, we want to thank our guest speakers from SpeakOUT Boston who joined us to share their personal stories and shed light on the challenges faced by LGBTQ+ individuals in the workplace. At Cullinan, we’re committed to cultivating an environment where everyone can feel seen, heard, and valued. As part of this commitment, we provide learning opportunities and support systems to enhance cultural competence and allyship within our organization and community. SpeakOUT reminded us that being an ally is not a noun, it’s a verb – our actions speak louder than words. We hope you will join us this Pride Month and beyond in taking action to ensure everyone in your community feels safe, supported, and celebrated for who they are. Happy Pride Month!
-
Team Cullinan was proud to participate in the 2024 Kendall Square Challenge earlier this month. Our team helped raise funds to support local nonprofit InnerCity Weightlifting (ICW). Thank you Kendall Square Association for hosting such a fun way to give back to our community!
-
Today, on Juneteenth, as part of our ongoing efforts to support organizations in our local community, we are proud to share that we have once again made a contribution to We Got Us. This Boston-based student-led coalition is dedicated to increasing access to equitable healthcare, community-centered health education, and direct healing for Black communities. We are committed to working towards a future where everyone has access to high-quality care, regardless of their race or socioeconomic status. We know that this work requires sustained effort and a willingness to listen, learn, and take action.